Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2025 16:32 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
October 07, 2025 06:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval and Positive Interim Clinical Data for LX2006 in FA Cardiomyopathy
August 14, 2025 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
July 07, 2025 07:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
May 27, 2025 07:31 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
May 12, 2025 07:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
April 07, 2025 06:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
March 24, 2025 07:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
November 13, 2024 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
January 09, 2020 10:24 ET | Source: Retrotope

Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)

LOS ALTOS, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Retrotope announced today that it has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of...